



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number.

0 159 168  
A2

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number: 85302404.0

⑭ Int. Cl.: A 61 K 47/00  
A 61 K 9/06

⑯ Date of filing: 05.04.84

⑰ Priority: 05.04.84 JP 66710/84  
13.02.85 JP 24393/85

⑮ Applicant: Takeda Chemical Industries, Ltd.  
27, Doshimachi 2-chome Higashi-ku  
Osaka-shi Osaka, 541(JP)

⑲ Date of publication of application:  
22.10.85 Bulletin 85/43

⑯ Inventor: Kigasawa, Kazuo  
7-701, 15 Nozawa 4-chome  
Setagaya-ku Tokyo 154(JP)

⑳ Designated Contracting States:  
BE CH DE FR GB IT U NL SE

⑰ Inventor: Ohizani, Hideaki  
57-3, Yotsukidai 1-chome  
Katsushika-ku Tokyo 124(JP)

⑱ Inventor: Tanaka, Makoto  
3-403, 2 Ochiai 4-chome  
Tama Tokyo 192-02(JP)

⑲ Inventor: Hayashida, Shigeru  
3-508, 2 Ochiai 4-chome  
Tama Tokyo 192-02(JP)

⑳ Representative: Myerscough, Philip Boyd et al.  
J.A.Kemp & Co. 14, South Square Gray's Inn  
London, WC1R 8EU(GB)

④ Soft patch drug preparation.

⑤ Drug preparations for external application having a stick-itself-to-the-skin property, so-called "soft patch", are provided. The preparations contain a drug, a water-soluble protein having an absorption-promoting effect, a polyhydric alcohol, a tackifier, and an oleaginous substance, and ensure an improved percutaneous absorption and bioavailability of the drugs, thus permitting an accurate control of drug dosage.

A2

0 159 168

"SOFT PATCH DRUG PREPARATION"

This invention relates to pharmaceutical  
5 preparations for external application.

As examples of pharmaceutical products for  
application to the skin, ointments, liquids, plasters,  
tapes, etc. are known. These preparations are,  
however, not fully satisfactory in regard to dosage  
10 establishment, release and penetrability of active  
component, bioavailability, feeling of use, etc.  
Taking ointments as an example, it is difficult to  
apply an accurate dose, which depends on the appli-  
cation area and thickness; and it has also been  
15 pointed out that these preparations cannot be  
expected to produce adequate systemic effects after  
percutaneous absorption. Moreover, in the case of  
external drugs as compared with oral and other  
products, the skin acts as a barrier to the absorption  
20 of the drug and their bioavailability is considerably  
low. Of late, new dosage forms generally called  
the drug delivery system are being developed, but they  
have been put to use only with a few specific drugs.  
Japanese Kokai Sho 56-71025 discloses hydrophilic  
25 and good water-holdable base for plaster containing  
gelatin, polyvinylalcohol or polyvinylpyrrolidone,  
sodium polyacrylate, carboxyvinyl polymer, polyhydric  
alcohol such as glycerin and water, in addition to,  
for example, methyl salicylate. But this process is  
30 not satisfactory yet.

In view of the above technical situation,  
the present inventors conducted an intensive re-  
search to develop pharmaceutical preparations for  
external use that would overcome the above-mentioned  
35 disadvantages and, as a result, found that external  
preparations containing a water-soluble protein

0159168

display an improved percutaneous absorption. The finding was followed by further studies which have resulted in the development of external preparations of this invention which ensure an improved bio-  
5 availability, permit an accurate control of drug dosage and are convenient to apply.

For the purpose of accomplishing the above objects, defined components inclusive of said water-soluble protein are incorporated in the preparations  
10 according to this invention. Thus, this invention relates to a soft pharmaceutical preparation for external application which contains the following components (a), (b), (c), (d), and (e) and has a stick-itself-to-the-skin property (the preparation  
15 will sometimes be referred to briefly as "soft patch").

- (a) a drug;
- (b) a water-soluble protein which has an absorption-promoting effect;
- (c) a polyhydric alcohol;
- (d) a tackifier; and
- (e) an oleaginous substance.

There is no limitation on the type of drug that can be used, provided that it can be absorbed percutaneously. Thus, the above-mentioned drug  
25 includes both the drugs topically applied for local effects and those administered for systemic effects. The topical drugs include the drugs administered for the purpose of curing diseases on the skin surface or under the skin or for protective conditioning  
30 of the skin, and display mainly local effects. The drugs for systemic administration are the drugs absorbed from the skin surface where they are applied and reach the target tissue or organ via the circulation to display mainly systemic effects. Such drugs  
35 include antimicrobial agents, antitumor drugs, vitamins, antidiabetics, enzymes, herb medicines,

crude extracts and other medicines which take effect  
in the circulatory system, nervous system, endocrine  
system, respiratory system, metabolic system, urinary  
organ system, and digestive organ systems, of which  
5 practical examples are partially listed below.

- (1) Analgesic antiinflammatory agents:  
acetaminophen, aspirin, salicylic acid, methyl  
salicylate, choline salicylate, glycol salicylate,  
2-menthol, camphor, mefenamic acid, flufenamic acid,  
10 indomethacin, diclofenac, alclofenac, ibuprofen,  
ketoprofen, naproxene, pranoprofen, fenoprofen,  
sulindac, fenbufen, clidanac, flurbiprofen, indoprofen,  
protizidic acid, fentiazac, tolmetin, tiaprofenic acid,  
bendazac, bufexamac, piroxicam, phenylbutazone,  
15 oxyphenbutazone, clofezone, pentazocine, mepirizole,  
etc.; (2) steroid antiinflammatory agents: hydro-  
cortizone, prednisolone, dexamethasone, triamcinolone  
acetonide, fluocinolone acetonide, fludrocortisone  
acetate, etc.; (3) antihistaminics or antiallergic  
agents: chlorpheniramine, glycyrrhizic acid, diphen-  
hydramine, peractin, etc.; (4) local anesthetics:  
benzocaine, procaine, dibucaine, lidocaine, etc.;  
(5) antimicrobial agents including antibacterial  
agents, antifungal agents, antimycotic agents and  
antiviral agents; tetracyclines such as oxytetra-  
cycline, penicillins such as ampicillin, cephalosporins  
such as ceftalotin, aminoglycosides such as kanamycin,  
macrolides such as erythromycin, chloramphenicol,  
iodides, nitrofrantoin, nystatin, amphotericin,  
20 fradicmycin, sulfonamides, purrolnitrin, clotrimazol,  
etc.; (6) antihypertensive agents: clonidine,  $\alpha$ -  
methyldopa, reserpine, syrosingopine, rescinnamine,  
cinnarizine, hydrazine, prazosin, etc.; (7) anti-  
hypertensive diuretics: theophylline, trichlor-  
30 methiazide, furosemide, tripamide, methylclothiazide,  
penfluzide, hydrothiazide, spironolactone, metolazone,

- etc.; (8) cardiotonics: digitalis, ubidecarenone, dopamine, etc.; (9) coronary vasodilators: nitroglycerin, isosorbitol dinitrate, erythritol tetranitrate, pentaerythritol tetranitrate, dipyridamole,  
5 dilazep, trapidil, trimetazidine, etc.; (10) vasoconstrictors: dihydroergotamine, dihydroergotoxine, etc.; (11)  $\beta$ -blockers or antiarrhythmic agents: pindolol, propranolol, etc.; (12) calcium antagonists and other circulatory organ agents:  
10 diltiazem, nifedipine, nicardipine, verapamil, bencyclane, ifenprodil tartarate, molsidomine, etc.; (13) anti-convulsants: nitrazepam, meprobamate, phenytoin, etc.; (14) agents for dizziness: isoprenaline, betahistine, scopolamine, etc.;  
15 (15) minor tranquilizers: diazepam, lorazepam, flunitrazepam, fluphenazine, etc.; (16) hypnotics and sedatives: phenobarbital, amobarbital, cyclobarbital, etc.; (17) muscle relaxants: tolperisone, baclofen, dantrolene sodium, cyclobenzaprine;  
20 (18) autonomic agents: atropine, levodopa, etc.; (19) respiratory agents: codeine, ephedrine, isoproterenol, dextromethorphan, orciprenaline, ipratropium bromide, cromglycic acid, etc.; (20) hormones or antihormones: corticotropin, oxytocin, 25 vasopressin, testosterone, progesterone, estradiol, salivary hormone, thyroid hormone, adrenal hormone, kallikrein, insulin, oxendolone, etc.; (21) vitamins: vitamins A, B, C, D, E and K and derivatives thereof, calciferols, mecabalamin, etc.; (22) antitumor agents: 5-fluorouracil and derivatives thereof, krestin, picibanil, ancitabine, cytarabine, etc.;  
30 (23) enzymes: lysozyme, urokinase, etc.; (24) herb medicines or crude extracts: glycyrrhiza, aloe, Sikon (Lithospermum Radix), etc.; (25) antiulcer agents: allantoin, aldioxa, alcloxa, N-methylscopolamine methylsulfate, etc.; (26) antidiabetics; etc.

The drugs mentioned above can be used in combination as required. Moreover, the above drugs may be used either in the free form or, if capable of forming salts, in the form of a salt with a 5 suitable acid or base. If the drugs have a carboxyl group, their esters can be employed.

The acid mentioned above may be an organic acid, for example, methanesulfonic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, 10 acetic acid, or an inorganic acid, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid. The base may be an organic base, for example, ammonia, triethylamine, or an inorganic base, for example, sodium hydroxide or potassium 15 hydroxide. The esters mentioned above may be alkyl esters, aryl esters, aralkyl esters, etc.

Among them, the drugs acting in the circulatory system, nervous system, endocrine system and respiratory system, antimicrobial agents and 20 enzymes are particularly used as preferable drugs for this invention.

Although this invention may be applied to all types of drugs as listed hereabove, among such drugs, the drugs which, when administered alone, 25 are not or only sparingly absorbed percutaneously, the drugs which, if administered orally, show only low rates of utilization in the body, for example, drugs with bioavailabilities of less than 80%, drugs which tend to produce many side effects, 30 drugs which are decomposed by digestive juice, etc. and have, therefore, to be administered by injection, and drugs which are subject to the first-pass effect in the liver, etc. are especially effective when this invention is applied.

The concentration of the drug need only 35 be that which exhibits the expected clinical effect,

and in many instances ranges from about 0.01 to 15 weight percent, preferably 0.05 to 10 weight percent, or more preferably 0.05 to 5 weight percent, based on the weight of the whole composition. The .5 dosage is adjusted according to the type of drug, object of medication, age and body weight of the patient, stage of disease, etc.

The water-soluble protein mentioned herein-before may be virtually any such protein that 10 promotes absorption of the drug used. Such a protein may be a naturally occurring protein or a non-natural protein. The former includes animal proteins and vegetable proteins, while the latter includes peptides artificially derived or synthesized. While there 15 are fields of technology where a sharp distinction is made between peptide and protein, peptides are included in the category of proteins for the purposes of this invention, this being in consideration of their action and effect.

20 Examples of said animal proteins include gelatin, solubilizable collagen, casein and its sodium salt, glue, and their hydrolysates. The gelatin and solubilizable collagen include the soluble proteins obtainable by acid or alkali hydrolysis or hot water treatment of proteins from animal 25 bones or skins and the products derived therefrom by suitable chemical modifications, for example, succinylation, maleylation, phthalation, and they range from about tens of thousand to hundred of 30 thousand in molecular weight. Typical of said vegetable proteins are soybean protein, for example, the protein obtainable by sedimentation and enzymatic treatment of the water-soluble fraction of solvent-extracted soybean cake, and soybean casein. The 35 peptides mentioned above include the peptides obtainable by homo- or hetero-condensation of amino acids

by such techniques as chemical synthesis, fermentation or semi-synthesis, and their molecular weights are generally in the range of a few hundred to tens of thousand. As such, the constituent amino acids of  
5 the peptides may be neutral, basic or/and acidic, optically active or/and racemic, natural or/and synthetic. In accordance with this invention, one ore more, preferably one or two, of such water-soluble proteins can be employed. For instance, gelatin can be used either  
10 alone or in admixture with casein or soybean protein. Moreover, in consideration of promotant effects on drug absorption, compatibility or dispersability with other components, ease of availability, etc.,  
15 gelatin, solubilizable collagen, casein, soybean protein, etc. are generally utilized with advantage.

The amount of said water-soluble protein need only be that which helps accomplish the objects of this invention, and preferably that which ensures a sufficient promoting effect on the percutaneous  
20 absorption of the drug used. For this purpose, the water-soluble protein is in many instances used in an amount substantially equal to or surpassing the amount of the drug, generally in a proportion of about 5 to 50 weight percent, preferably about 5 to  
25 35 weight percent, more preferably 10 to 30 weight percent, based on the whole composition.

The above-mentioned polyhydric alcohols may include those having 2 to 6 alcoholic hydroxyl groups. Such polyhydric alcohols include glycols,  
30 triols and polyols having 4 to 6 alcoholic hydroxyl groups. Typical of said glycols are glycols containing 2 to 6 carbon atoms, e.g. ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol (average molecular weight about 200-8,000,  
35 preferably about 200 to 6,000), etc. Examples of said triols include glycerin, trimethylolpropane, etc.

Said polyols are exemplified by sorbitol (sorbit), polyvinylpyrrolidone, etc. These polyhydric alcohols may be used either singly or in combination (preferably, of two or three). Thus, for example, glycerin alone or  
5. a mixture of glycerin and butylene glycol is employed.

Among those polyhydric alcohols, those which satisfy the requirements such as the adjustment and maintenance of softness of the external drug of the invention, compatibility or co-dispersibility  
10 with the other components, and sufficient wettability of the product at application, may be freely used, and especially those which are low in volatility and plastic, are generally preferred and, in this sense, glycerin, propylene glycol, butylene glycol,  
15 sorbitol, etc. may be commonly employed.

The proportion of said polyhydric alcohols depends on the purpose of incorporation, types of other components, etc. and cannot be stated in general terms but may generally range from about 5  
20 to 50 weight percent, preferably from about 5 to 35 weight percent, more preferably 10 to 30 weight percent, based on the whole composition.

As to the tackifier referred to herein-before, a substance or substances capable of providing  
25 the preparation with adequate adhesivity to the skin may be used. Preferred tackifiers are those which not only bestow adhesivity to the skin but serve the purpose of assisting in the maintenance of flexibility of the product itself and that of preventing evaporation of water and others through formation  
30 of a surface film. Thus, cellulose derivatives, polysaccharides, carboxyvinyl polymers, polyvinyl alcohol, polyvinylpyrrolidone, etc. may be mentioned as typical tackifiers.

35 The above-mentioned cellulose derivatives include alkylcelluloses and hydroxyalkylcellulose

whose average molecular weights are in the range of about 40,000 to 200,000 and whose alkyl moieties contain 1 to 4 carbon atoms, e.g. methylcellulose, ethylcellulose, propylcellulose, methylpropylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and carboxymethylcellulose and its alkali metal salts, etc.

- 5 Examples of said polysaccharides include simple polysaccharides such as starch and its derivatives, e.g. carboxymethylstarch, hydroxypropyl-starch, dextrin, dextran, chitin, alginic acid and its sodium salt, glycogen, Pluran® (the trademark of Hayashibara in Japan), carrageenan, etc., and complex polysaccharides such as mannan, peptin, gum arabic, 10 Karaya gum, etc.

The above-mentioned carboxyvinyl polymers are those having average molecular weights in the range of about 900,000 to 3,000,000, and include polyacrylic acid, polymethacrylic acid and their 15 alkali metal salts. To be specific, such commercial products as Hiviswako® (the trademark of Wako Pure Chemical Industries, Ltd. in Japan), Carbopol® (the trademark of Goodrich in U.S.A.), Luviskol® (the trademark of BASF in West Germany), etc. can be advantageously employed. The tackifiers mentioned above are used either 20 singly or in combination (preferably, of two or three).

In using such a tackifier in the practice of invention, its proportion should be such that the above-mentioned objects are fulfilled and, thus, 25 generally ranges from about 0.1 to 15 weight percent and preferably from about 0.3 to 10 weight percent, more preferably 0.5 to 10 weight percent, relative to the whole preparation.

As the oleaginous substance referred to hereinbefore, fatty acid esters, aliphatic higher alcohol, paraffin oil, lanolin oil, silicone oil,

Plastibase<sup>®</sup> (the trademark of Squibb and Sons, U.S.A.) may be used.

Said fatty acid esters are esters of aliphatic carboxylic acid with aliphatic alcohol, which may be either synthetic products or natural products. The range of this aliphatic carboxylic acid includes saturated or unsaturated aliphatic mono- or di-carboxylic acid, of which representative example includes lower to higher fatty acid having 2 to 24 carbon atoms, and among them middle to higher fatty acid containing 6 to 20 carbon atoms are often used as preferable ones. Their practical examples include acetic acid, propionic acid, hexanoic acid, capric acid, caprylic acid, octanoic acid, dioctanoic acid, adipic acid, sebacic acid, palmitic acid, stearic acid, oleic acid, linolic acid, linolenic acid, and myristic acid.

Examples of said aliphatic alcohol are saturated or unsaturated aliphatic monoools or triols having 1 to 30, preferably 1 to 20 carbon atoms and polyols having 4 to 8 hydroxyl groups. Examples of said monoools include straight-chain or branch alcohols, for example, methanol, ethanol, propanol, butanol, hexanol, octanol, decanol, hexadecanol, octyldodecyl-alcohol, palmitylalcohol, stearylalcohol, and myristylalcohol. An example of triols is glycerin, and said polyols may be represented by sorbitol (sorbit) and cane sugar. As the esters of said aliphatic carboxylic acid and aliphatic alcohol, those of which carboxylic groups and alcoholic hydroxyl groups in the molecule are wholly engaged in the esterification (complete esters) are preferable, or as the case may be, those in which one of carboxylic groups in the aliphatic dicarboxylic acid molecule or/and part of hydroxyl group in tri- or poly-ol molecule is freed (partial esters) may be

used, or esters of mixed acid group may be also used.

Above all, middle to higher fatty acid glyceride or triglyceride having 6 to 20 carbon atoms, complete esters of middle to higher fatty acid having 5 6 to 20 carbon atoms and aliphatic monool having 1 to 20 carbon atoms, or partial esters with polyol may be preferably used. Examples of said fatty acid esters are isopropyl myristate, octyldodecyl myristate, myristyl myristate, isoprpyl palmitate, butyl 10 stearate, decyl oleate, diisopropyl adipate, diethyl sebacate, hexyldecyl dioctanate, sorbitan mono-palmitate, cane sugar fatty acid ester, triacetyn, di- or tri-glyceride caprylate, di- or tri-glyceride caprate, mixed acid group triglyceride comprising 15 capric acid and caprylic acid, di- or tri-glyceride oleate, di- or tri-glyceride linolate, and mixed acid group triglyceride comprising oleic acid and linolic acid.

Such fatty acid esters may be used either 20 in a pure or nearly pure state as in synthetic products, or in a mixed state with other substances as in natural products. Former examples are the substances exemplified hereabove being used directly, whereas latter examples may include natural oils and fats, 25 such lard, tallow, whale wax and other animal oils, or soybean oil, sesame oil, cotton seed oil, palm oil, olive oil, castor oil, beeswax and other vegetable oils.

Examples of said aliphatic higher alcohols 30 are represented by saturated or unsaturated aliphatic alcohols having 14 to 20 carbon atoms, such as cetanol (palmityl alcohol), stearyl alcohol, oleyl alcohol, and hexadecyl alcohol.

35 Examples of said paraffin oils are mainly composed of paraffin mixtures having 15 or more carbon

atoms, and practically are liquid paraffin, vaseline including white vaseline, squalane, and squalene, and particularly liquid paraffin, white vaseline and squalane are often used preferably.

5 Examples of said silicone oils are polymer mixtures of dimethyl siloxane, e.g. dimethyl polysiloxane, and its alkyl ester, methyl phenyl polysiloxane, glycolmethyl siloxane, etc.

10 Examples of said lanolin oils are lanolin, lanolin wax, hydrogenated or reduced lanolin and its ethylene oxide polymer, and among them lanolin is often used most preferably.

15 The chemical composition of this lanolin is usually as follows: alcohols, e.g. cetyl alcohol, lanolin alcohol, carnaubyl alcohol, by 30 to 35 weight percent, cholesterins, e.g. cholesterin, isoocholesterin, methacholesterin, by 15 to 20 weight percent, fatty acids, e.g. acetic acid, lactic acid, caproic acid, myristic acid, stearic acid, lanostearic acid, by 45 to 55 weight percent, etc.

20 Among these oleaginous substances, those having an action to promote the percutaneous absorption of the drug and an action to enhance the solubility of the drug and nonirritant to the skin are particularly used preferably. Such oleaginous substances exist mostly in a liquid or paste state, or sometimes in a wax state, and may be used regardless of the state, and usually commercial products may be used advantageously.

25 30 In this invention, the above-mentioned oleaginous substances may be used either singly or in combination (preferably, of two to four).

35 The proportion of said oleaginous substances depends on the purpose of the invention, and usually ranges from 0.1 to 25 weight percent, preferably 0.5 to 20 weight percent, or more preferably 0.5 to 15

weight percent, based on the whole composition.

In addition to the above components, for the purpose of maintaining the product characteristics such as softness and drug absorption of the soft patch, an appropriate amount of water may be added. The proportion of water is generally about 20 to 80 weight percent, preferably 30 to 75 weight percent, or more preferably 35 to 70 weight percent, based on the whole preparation.

In addition of above components, for the purpose of permitting the desired characteristics of the soft patch to be fully materialized, other additives may also be used as necessary. Such additives may be known substances, examples of which are as follows.

(1) Absorption promoting auxiliaries (substances that contribute to the absorption of drugs through promotion of softening of the horny layer, improvement of water retention or absorption, dilatation of pores of the skin, etc.): Urea, salo-column, 1-n-dodecylazocycloheptan-2-one (trademark: Azon®, Nelson Research Development Co. in U.S.A.), dimethyl sulfoxide, dodecyl sulfoxide, dimethylformamide, dimethylacetamide, toluyl diethylamide, tetrahydro-furfuryl alcohol, dodecylpyrrolidone, 2-pyrrolidone, methylpyrrolidone, allantoin, salicylic acid, etc. When such an absorption-promoting auxiliary agent as above is employed, its proportion is generally about 0.05 to 5 weight percent, preferably 0.1 to 5 weight percent, based on the whole preparation.

(2) Preservatives (substances which prevent degradation or putrefaction due to micro-organisms): p-Hydroxybenzoic acid alkyl esters (parabens), sorbic acid, dehydroacetic acid, etc. When such a preservative is employed, its proportion is generally about 0.05 to 2 weight percent, prefer-

ably 0.1 to 1 weight percent, relative to the whole preparation.

(3) Emulsified-dispersants (substances that contribute to a uniform dispersion of the components, etc.): Nonionic surfactants such as polyoxyethylene fatty acid esters, Polysorbate 80, etc., anionic surfactants such as sodium lauryl-sulfate, etc., lower alcohols such as ethanol, etc., acetone and so on. When such an emulsifier-dispersant is employed, its final concentration is generally about 0.05 to 5.0 weight percent, preferably 0.1 to 3 weight percent, relative to the whole preparation.

(4) pH-controlling agents (substances possessing abilities to stabilize the components, lessen the irritation to the skin, and maintain the absorption of drug through controlling of pH): Organic acids, e.g. citric acid, tartaric acid, lactic acid, or inorganic acids, e.g. hydrochloric acid, sulfuric acid, phosphoric acid, or their alkaline metal salts. When such a pH-controlling agent is used, its proportion is generally about 0.1 to 5 weight percent, preferably 0.5 to 5 weight percent, relative to the whole preparation.

(5) Colors: Water-soluble tar colors, natural colors, etc.

In the practice of this invention, unlike in the production of the conventional gelatin cataplasm, it is not necessary to use a crosslinking agent, e.g. aldehydes, or a stringent, e.g. zinc oxide, kaolin. Rather, such additives may detract from the softness of the preparation.

The dimensions of the unit dosage form of the soft patch composed of the above components are optional only if the soft patch has a size and shape permitting easy application to the skin surface. Thus, generally, it may be shaped like a sheet, a

disk, a ribbon or the like, which has a suitable thickness and area (the effective area to come in contact with the skin surface when applied). The above-mentioned thickness is generally about 0.2 to 5 mm and preferably about 0.3 to 2.0 mm. The area is generally about 0.08 to 200 cm<sup>2</sup> and preferably about 0.2 to 160 cm<sup>2</sup>. Thus, taking a sheet-shaped soft patch as an example, its area may generally be about 0.2 by 0.4 cm to 10 by 20 cm and preferably 10 be about 0.4 by 0.5 cm to 10 by 16 cm. In the case of disk or ribbon-shaped soft patches, too, various sizes may be selected from within the above-mentioned range. Which of these shapes to choose depends upon the administration site, therapeutic purpose, etc.

15 The soft patch having any of the above-mentioned shapes is generally made available in independent single-dose units but for convenience in use, it may be made available as a sheet provided with incisions or scores for severing it into single-dose units, as an integral sheet from which several 20 to tens of dose units can be serially cut off with scissors or the like, or as a roll of the ribbon-shaped soft patch.

When the soft patch is covered with 25 a suitable packaging film on one side or both sides thereof for the ease of use, storage or handling, the film is removed in use and the exposed medicated side is applied to the skin. Such a packaged product is convenient in many cases. Therefore, the soft patch 30 can be made available in the various alternative forms described below. (1) No packaging film is used at all. (2) A packaging film is used on one side only. (3) A packaging film is used on both sides. As the packaging film, a flexible film having a thickness of about 0.02 to 0.8 mm, such as synthetic resin 35

elastomer film, butadiene polymer film, isoprene polymer film, etc., cellophane film, etc. can be employed. A woven or nonwoven fabric may also be employed.

5 When the soft patch contains a volatile component or there is a risk of contamination during storage, it is preferably stored in a sealed container, e.g. aluminum pack, polyethylene pouch, moisture-proof bag, etc.

10 The external preparation according to this invention is generally soft in texture. As will be seen from the fact that it has a softness allowing some degree of deformation without losing its integrity, the external preparation of this invention 15 has adequate flexibility and elasticity so that, for example, it can be easily stretched or dented by application of minor external forces. Therefore, it fits the skin well and provides a good feeling of use. It should be understood that the concept of 20 softness in the context of this invention covers the case in which the softness of the soft patch increases when its surface is wetted with water, for instance.

25 The soft patch having the above-described construction is applied for therapeutic purposes to the skin of the body at the site suitable for the therapeutic purpose, subject, etc. For example, for topical administration, the soft patch is applied directly to the affected site or in the neighborhood thereof. For systemic application, it is applied to 30 a site which is most conductive to the percutaneous absorption of the active component, e.g. where the horny layer has not been well developed, or a site which does not give a substantial foreign sensation to the patient. Furthermore, the known cosmetic 35 ingredients may be incorporated for use as a cosmetic product (prevention of rough skin, sun-burn, etc.).

As regards the production of the soft patch, a variety of processes may be utilized unless they are in conflict with the purposes of this invention. For example, the existing processes for 5 the production of pharmaceutical products such as suppositories, cakes and confections such as chewing gum, jellies, chocolate, etc. or foods such as noodles may be modified in part to utilize them as the production processes for the soft patch of this 10 invention. Such modifications are those necessary for the maintenance of softness, improvement of drug absorption, etc. which are the objects of this invention. A convenient production method is as follows. The above-mentioned drug, water-soluble 15 protein, polyhydric alcohol, tackifier and oleaginous substance are mixed in a suitable sequence and the mixture is molded into a product having a suitable shape. To be specific, (a), (1) a mixture of water-soluble protein and water, (2) a mixture of drug, 20 polyhydric alcohol, oleaginous substance and water (to which the above-mentioned additives are added at this stage), and (3) a mixture of tackifier and water are respectively prepared. Then, (4) the above mixtures are blended generally in the order 25 mentioned and stirred until a homogenous mixture is obtained. Finally, (5) in the molding stage, it may generally be cast in a vessel having suitable thickness and dimensions or compression-molded using a suitable mold and the molding is then cut, 30 punched or otherwise processed into the unit dosage form. In an alternative process, (b), a liquid other than water, e.g. a polyhydric alcohol may be used in lieu of water. In still another alternative process, (c), the components are comminuted or kneaded 35 irrespective of the presence of water, and the mixture is compression-molded using a suitable mold.

In the course of the above process or thereafter, the above-mentioned packaging film may be applied. Since the above method consists of simple and expedient steps, it can be advantageously practiced on a commercial scale and permits production of the soft patch in a variety of shapes and forms suitable for varied uses. Moreover, even drugs which are either liquid or low-melting and could not be incorporated in the conventional solid preparations can now be incorporated by the process described above.

The following examples illustrate the method of producing the external preparation of this invention. The formulas of the products described in the examples are shown in Table I.

Example 1 Clidanac-containing preparation; pharmaceutical compositions will herein-after be referred to in the like manner.

- According to the formula given in Table I,
- 20 (1) 15 g of gelatin was put in 30 g of purified water and dissolved by warming at 50°C;
  - (2) 1 g of Pluran® and 1 g of polyvinyl alcohol were dissolved in 17.7 g of purified water;
  - 25 (3) 0.5 g of sodium polyacrylate was dissolved in 10 g of purified water;
  - (4) in a mixture of 23 g of glycerin, 0.5 g of diisopropyl adipinate and 0.2 g of Polysorbate 80 were suspended 1 g of clidanac and 0.1 g of paraben with warming at 50°C;
  - 30 (5) the solution (2) was added to the solution (1) and the mixture was stirred at the same temperature as above using a homomixer;
  - 35 (6) the solution (3) was added to the above mixture (5) and the whole mixture was stirred in the homomixer at the same temperature; and

(7) the suspension (4) was added to the above mixture (6) and the whole mixture was stirred in the homomixer at the same temperature and, then, cast into a mold in a thickness of 1 mm over a polyethylene packaging film, and was cut to give a soft patch in the shape of a sheet measuring 6 cm (length) by 4 cm (width).

#### Example 2 Pindolol-containing preparation.

10 The bulk product prepared by the same procedure as Example 1 in accordance with the formula of Table 1 was shaped into a ribbon measuring 1 mm in thickness and 2.0 cm in width. After application of a packaging film, the ribbon was rolled up in the shape of a coil.

#### Example 3 Clidanac-containing preparation

The bulk product prepared in the same procedure as Example 1 in accordance with the formula of Table 1 was cut into a sheet-shaped product measuring 1 mm in thickness by 13 cm in length by 10 cm in width.

#### **Example 4 Ifenprodil tartrate-containing preparation.**

According to the formula given in Table 1.

(1) 2 g of sodium citrate was dissolved in 32.3 g of purified water, and 20 g of gelatin and 2 g of Pluran were added to wet, and dissolved by warming at 50°C;

(2) 0.5 g of sodium polyacrylate was dissolved in 5 g of purified water;

(3) 1 g of Polysorbate 80 was dissolved in 5 g of purified water.

(4) 1 g of ifenprodil tartrate and 0.2 g of paraben were added to 23 g of glycerin, and dissolved by warming at 70°C:

(5) 5 g of middle-chain fatty acid tri-glyceride and 3 g of white vaseline were uniformly mixed by warming at 50°C; and

5       (6) in a homomixer heated to 50°C, solutions (2) and (3) were first added to mixture (1), and solution (4) was added, then finally solution (5) was added, and the whole mixture was stirred and cast into a mold. After cooling, the casting was cut to give a soft patch containing 20 mg of  
10 ifenprodil tartrate in a thin film measuring 6.5 cm in length by 6.5 cm in width by 0.4 mm in thickness.

Examples 5-22 Ifenprodil tartrate-containing preparations.

15       According to the formula of Table 1, soft patches were prepared in the same manner as Example 4. The obtained bulk products were manufactured into a disk-shaped film soft patch measuring 0.4 mm in thickness by 30 mm in diameter by blanking or cutting  
20 in Example 7, into a tape-formed soft patch with polyethylene packaging film measuring 0.4 mm in thickness by 2.5 cm in width being rolled up in a coil in Example 9, and into a soft patch similar to the form in Example 4 in all other examples.

25       Examples 23-27 Clonidine hydrochloride-containing preparations.

30       The bulk products obtained by the same procedure as Example 4 in accordance with the formula of Table 1 were cut to manufacture thin film soft patches containing 0.3 mg of clonidine hydrochloride measuring 2 cm in length by 2 cm in width by 0.4 mm in thickness.

35       Examples 28-32 Nifedipine-containing preparations.  
According to the formula of Table 1, soft

patches were prepared in the same manner as Example 4.

Examples 33-35 Prazocin hydrochloride-containing preparations.

5 The bulk products obtained by the same procedure as Example 4 in accordance with the formula of Table 1 were cut to manufacture thin film soft patches containing prazosin hydrochloride by 1 mg measuring 2 cm in length by 2 cm in width by 0.4 mm  
10 in thickness.

Examples 36-40 Clidanac-containing preparations.

In Example 36, according to the formula given in Table 1,

15 (1) 20 g of gelatin and 2 g of Pluran were wetted in 41.3 g of purified water, and dissolved by warming at 50°C;

(2) 0.2 g of paraben was dissolved in 23 g of glycerin by warming at 50°C;

20 (3) 0.5 g of sodium polyacrylate was dissolved in 5 g of purified water;

(4) 1 g of Polysorbate 80 was dissolved in 5 g of purified water;

25 (5) 0.5 g of clidanac was added to 1.5 g of diisopropyl adipinate, and dissolved by warming at 50°C; and

(6) in a homomixer heated to 50°C, first solutions (2), (3) and (4) were added to mixture (1), and solution (5) was added, and the whole mixture 30 was stirred, and cast in a mold. Thereafter, a soft patch was prepared in the same manner as Example 4.

In Examples 37-40, soft patches were prepared according to the formula of Table 1 in the same manner as Example 36.

Examples 41-47 Pindolol-containing preparations.

According to the formula of Table 1, soft patches were prepared in the same manner as Example 36.

5

Examples 48-51 Propranolol hydrochloride-containing preparations.

In Example 48, according to the formula given in Table 1,

- 10 (1) 3 g of sodium citrate was dissolved in 20 g of purified water, and 20 g of gelatin was added to wet, and dissolved by warming at 50°C;
- (2) 10 g of casein sodium was dissolved in 10 g of purified water;
- 15 (3) 0.2 g of paraben was added to 20 g of glycerin, and dissolved by warming at 50°C, and 1 g of methyl cellulose was added to the solution;
- (4) 1 g of Polysorbate 80 was dissolved in 5 g of purified water;
- 20 (5) 0.95 g of propranolol hydrochloride was dissolved in the remaining purified water;
- (6) a mixture of 1 g of squalane and 3 g of octyldodecyl myristate was heated to 50°C; and
- 25 (7) in a homomixer heated to 50°C, first solutions (2), (3) and (4) were added to mixture (1), and solution (5) then solution (6) were added, and the whole mixture was stirred and cast into a mold. Thereafter, in the same manner as in Example 4, a soft patch was prepared.

30 In Examples 49-51, soft patches were prepared by the same procedure as Example 48 in accordance with the formula of Table 1.

Examples 52-56 Isosorbit nitrate-containing preparations.

35 In Example 52, according to the formula

given in Table 1.

(1) 30 g of purified water was added to wet 20 g of gelatin, which was dissolved by warming at 50°C;

5 (2) 0.2 g of paraben was added to 10 g of glycerin, and was dissolved by warming at 50°C, then, after cooling, 2 g of karaya gum was added and suspended;

10 (3) 1 g of Polysorbate 80 was dissolved in 5 g of purified water;

(4) 1.25 g of isosorbit nitrate was suspended in sorbitol 5 g and remaining purified water;

(5) 4.5 g of squalane was heated to 50°C; and

15 (6) in a homomixer heated to 50°C, first solution (2) and (3) were added to mixture (1), and solution (4) was added then solution (5) was added, and the whole mixture was stirred and cast in a mold. Thereafter, in the same manner as in Example 4, a soft patch was prepared,

In Examples 53-56, soft patches were prepared by the same procedure as Example 52 in accordance with the formula of Table 1.

25 Examples 57-59 N-methyl scopolamine methyl sulfate-containing preparations.

In Example 57, according to the formula given in Table 1,

30 (1) 30 g of purified water was added to wet 20 g of gelatin, which was dissolved by warming at 50°C;

(2) 10 g of purified water was added to 1 g of carrageenan to wet;

35 (3) 0.2 g of paraben was added to 20 g of glycerin, and dissolved by warming at 50°C;

(4) 1 g of Polysorbate 80 was dissolved

(5) 0.095 g of N-methyl scopolamine methyl sulfate was added to the remaining purified water;

5 (6) a mixture of 3 g of silicone oil and 2 g of squalane was heated to 50°C; and

(7) in a homomixer heated to 50°C, first solutions (2), (3) and (4) were added to mixture (1), and solution (5) then solution (6) were added, and the whole mixture was stirred and cast into a mold.

10 Thereafter, a soft patch was prepared in the same manner as Example 4.

In Examples 58-59, soft patches were prepared according to the formula of Table 1 in the same manner as Example 57.

15 Examples 60-61 Piroxicam-containing preparations.

According to the formula of Table 1, soft patches were prepared in the same manner as Example 4.

20

0159168

Table 1 Note 1) (1)

able 1 (1) continued

lite vaseline		3		*	3	3	
liquid paraffin		.5					
refined lanolin							
ethanol							3
early alcohol							3
isopropyl myristate							
silicone oil							1
triodecyl myristate							
glycerbte 80	0.2	0.1		1	1	1	1
cotamiton							
sodium citrate			2	2	2	2	3
ether absorption promoting auxiliaries (Note 3)					2		
uraben	0.1	0.1	0.2	0.2	0.2	0.2	0.2
distilled water	57.7	58.8	53.7	42.3	41.3	40.3	47.3
							49.3
							40.3
							39.3

note 1) All amounts are by weight (g).

note 2) ODO ③ (mixed caprylic-capric acid (75:25) triglyceride, manufactured by Nisshin Seiyu Kabushiki Kaisha in Japan)

note 3) Example 6: Azone ④; Example 25: urea; Example 26: allantoin; Example 27: salicylic acid; Example 42: Azone ④; Example 43: N-methyl-2-pyrrolidone; Example 44: 2-pyrrolidone; Example 45: N,N-dimethylacetamide.

Variable 1 Note 1) (2)

Table 1 (2) continued

Table 1 Note 1 (3)

Table 1 (3) continued

table 1 Note 1) (4)

Material/Example	37	38	39	40	41	42	43	44	45	46	47	48
drug	0.5	0.5	0.5	1	1	1	1	1	1	1	1	0.95
gelatin	20	20	20	20	20	20	20	20	20	20	20	20
zasein sodium												10
glycerin	23	23	20	20	20	20	20	20	20	20	17	20
propylene glycol												
sorbitol (70%)												
butylene glycol			2								2	
polyethylene glycol												
luram®	2	2	2	2	2	2	2	2	2	2	2	2
polyvinyl alcohol												
ethylcellulose												
hydroxyethylcellulose												
sodium polyacrylate	0.5	0.5	0.5		0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
sodium alginate												
polyvinylpyrrolidone												
liviswako® 105												
taraya gum												

ble 1 (4) continued

- 32 -

0159168

fragran	
malane	1
dium-chain fatty acid	
glyceride (Note 2)	
isopropyl adipinate	1.5
ethyl sebacate	1.5
ite vaseline	
uid paraffin	2
rified lanolin	
anol	
earyl alcohol	
opropyl myristate	2
ilicene oil	
etylodecyl myristate	
lysorbate 80	1
otaniton	
odium citrate	
ther absorption Promot-	
ng auxiliaries (Note 3)	
araben	
istilled water	51.3 50.8
	52.3 53.5
	52.5 51.5
	49.0 52.0
	50.0 53.0
	42.69

Table 1 (5)

Material/Example	49	50	51	52	53	54	55	56	57	58	59	60	61
Drug	0.95	0.95	0.95	1.25	1.25	1.25	1.25	1.25	0.095	0.095	0.095	0.12	0.02
Gelatin	20	15	10	20	17	20	17	20	20	15	20	20	20
Casein sodium										10	5		
Glycerin			10	10	10	17	5	20	20		13	23	25
Propylene glycol	2				3					1			
Sorbitol (70%)	10	10	5	5		10				7	7		
Butylene glycol	3									3			
Polyethylene glycol					5								
Pluram ®													2
Polyvinyl alcohol						2	2	2					
Methylcellulose			1								1		
Hydroxyethylcellulose					2	2							
Sodium polyacrylate	0.4			0.5	0.5	0.5				0.5	0.5	0.5	0.5
Sodium alginate													
Polyvinyl pyrrolidone								2	2				
Tividawako ® 105			0.3										
Taraya gum	2				2	2	1			1	1.5		

Table 1 (5) continued

The external preparation obtainable by the above method of this invention can be stored in stable condition, and when applied, ensures adequate tackiness and adhesivity to the human skin and mucosa with a good feeling of use. Left on the skin for a long time, it does not cause side effects such as contact dermatitis, and can be easily detached after use. Thus, having the characteristics summarized below, the preparation according to this invention has great clinical and industrial values.

(a) Compared with the conventional external drugs such as ointments, the preparation of this invention is convenient in use and permits easy control of dosage. Therefore, one may avoid occurrence of side effects and losses of the drug due to overdosing or inadequate efficacies due to underdosing, thus instituting a pin-pointed regimen for each therapeutic purpose and each disease.

(b) The preparation ensures a high percutaneous absorption of the active component drug. Therefore, not only local effects but also the systemic effects can be expected.

(c) Being a soft preparation, the preparation is flexible and offers good contact with the skin and a satisfactory feeling of use.

(d) The drugs which would cause side effects, e.g. gastrointestinal disorders, or poor bioavailability can be effectively used in an improved manner, e.g. delayed metabolism.

(e) When the treatment regimen calls for several oral intakes a day, the patient may forget or dislike the taking of the drug. There also are cases in which many different drugs must be taken in large amounts. In such cases, the soft patch according to this invention ensures many hours of sustained efficacy at the application interval of once or twice daily. Thus, it is easy for the patient to use and

for the doctor to control both the disease and drug effect.

The test examples of this invention are given below.

5

Test Example 1 Sensory test on feeling of use such as fitness, adhesion, etc.

Using the soft patch of the formula of Example 4 from which the drug had been removed, a 10 sensory test was performed in duplicate using a panel of 10 adults in accordance with Scheffe's method described in Handbook of Sensory Tests, New Edition, pages 356-366 (The Japanese Federation of Science and Technology). Thus, test samples were applied 15 to the right and left upper arms and, after 2 hours, removed. The panelists were asked to evaluate the feeling of use for each of the right and left arms and to score it on the following scale: much better (+3), certainly better (+2), somewhat better (+1), 20 no different (0), somewhat worse (-1), worse (-2) and much worse (-3).

The ultimate mean score about the feeling of use of the above soft patch was  $+2.04 \pm 0.78$ . The concurrent test with the commercial control plaster 25 gave the score of  $-0.73 \pm 0.83$ . Aside from the above result, the panelists pointed out that the feeling of the soft patch to the skin was superior to the conventional external drugs.

30 Test Example 2 Serum concentration after administration of ifenprodil tartrate-containing preparation.

Method

35 The hairs on the back of male albino rabbits (weighing 3.1 to 4.3 kg, groups of 3 rabbits) were clipped off with electric clippers with care not to

injure the skin on the day before administration of test materials, and the following external preparations (C) to (I) of this invention were applied to the clipped area. Separately, by way of comparison, 5 external preparation (B) and oral preparation (A) not containing oleaginous substance were prepared and applied. For both external and oral routes, the dosage was equally 10 mg/kg of ifenprodil tartrate.

(A) Aqueous solution containing 0.15% of 10 ifenprodil tartrate.

(B) This external preparation was made as follows:

(1) 20 g of gelatin was wetted in 30 g of purified water, and dissolved by warming at 50°C;

15 (2) 5 g of Pluran was dissolved in 10 g of purified water;

(3) 23 g of glycerin, 0.2 g of paraben, and 1 g of ifenprodil tartrate were added to 10.8 g of purified water, and blended well by warming at 20 50°C; and

(4) in a homomixer heated to 50°C, first solution (2) was added to solution (1), then solution (3) was added, and the whole mixture was stirred, and cast into a mold. After cooling, the molding 25 was cut to make a thin film soft patch measuring 6.5 cm in length by 6.5 cm in width by 0.4 mm in thickness.

(C) A soft patch according to Example 10.

(D) A soft patch according to Example 11.

30 (E) A soft patch according to Example 12.

(F) A soft patch according to Example 13.

(G) A soft patch according to Example 14.

(H) A soft patch according to Example 15.

(I) A soft patch according to Example 16.

35 Blood samples of 3.5 to 4 ml aliquots were taken at timed intervals in 0.25 to 8 hours after

administration in groups (A) and (B), and in 2 to  
30 hours in groups (C) to (I), and the serum was  
separated by centrifugation. A 2 ml portion of the  
serum was extracted with ether and the extract was  
5 reacted with pentafluorobenzyl bromide in the  
presence of a strong alkali, and then with bis(trimethylsilyl)trifluoroacetamide. The resulting  
derivative was assayed by ECD-gas chromatography  
(<sup>63</sup>Ni, model GLC-4CM of Shimadzu Corporation).

10 Results

The results are set forth in Table 2, which  
discloses the following findings:

15 (1) The AUC (area under serum concentration)  
of the soft patch (B) was about half that of oral  
preparation (A).

20 (2) In the soft patches (C) to (I) which  
have oleaginous substances added to this soft patch  
(B), higher concentrations in the blood, longer  
persistance thereof, and higher AUC values were  
commonly noted as compared with those of (A) and (B)  
above. In particular, the soft patch (G) showed  
a Cmax (the maximum concentration in serum) of about .4  
times higher, and the AUC value of about 24 times higher  
than (A).

Table 3 Serum Concentration of Ifenprodil (Unchanged Form) (ng/ml)

Group	Time (hr)	0.25	0.5	1	2	4	6	8	AUC (ng·hr·ml <sup>-1</sup> )
(A)	1.0 ± 1.0	1.9 ± 1.0	5.0 ± 0.2	3.4 ± 0.4	3.2 ± 0.6	0	-	-	16.3 ± 1.1
(B)	-	-	1.9 ± 0.7	2.5 ± 1.0	0.8 ± 0.3	0.8 ± 0.2	0.5 ± 0.3	8.9 ± 1.7	

Group	Time (hr)	2	4	8	24	28	30	AUC (ng·hr·ml <sup>-1</sup> )
(C)	0.4 ± 0.3	0.6 ± 0.2	1.1 ± 0.4	4.8 ± 2.7	-	-	-	51.8 ± 25.3
(D)	1.5 ± 0.2	1.7 ± 0.4	4.2 ± 0.3	3.2 ± 0.4	2.5 ± 0.2	2.4 ± 0.1	92.4 ± 8.3	
(E)	1.9 ± 0.3	3.1 ± 0.8	7.3 ± 2.5	18.0 ± 4.4	4.9 ± 0.5	3.3 ± 0.3	286.0 ± 71.1	
(F)	1.0 ± 0.9	4.4 ± 2.6	6.4 ± 2.8	12.2 ± 2.5	3.3 ± 0.9	3.5 ± 1.3	215.1 ± 59.7	
(G)	0.6 ± 0.2	4.6 ± 1.5	15.5 ± 4.3	19.3 ± 0.8	9.0 ± 1.6	5.7 ± 0.5	395.5 ± 41.6	
(H)	2.3 ± 1.2	3.7 ± 1.8	6.0 ± 3.0	9.6 ± 3.2	4.0 ± 0.8	4.0 ± 0.9	188.0 ± 62.7	
(I)	1.1 ± 0.2	1.1 ± 0.1	4.7 ± 1.9	14.1 ± 2.3	4.8 ± 0.6	3.1 ± 0.4	209.8 ± 38.9	

Test Example 3 Serum concentration after administration of piroxicam-containing preparation.

Method

5 Part of dorsal hair of male SD rats (weighing 250 to 290 g, groups of 3 rats) was clipped off, and the following test materials (A) and (B) were attached or applied to the clipped area ( $3\text{ cm} \times 3\text{ cm} = 9\text{ cm}^2$ ). The dosage was 0.5 mg/kg of piroxicam.

10 (A) A soft patch according to Example 60.

(B) A known preparation: An ointment containing piroxicam as disclosed in the Japanese Kokai Sho. 59-13714 comprising 0.5 g of piroxicam, 1.0 g of Hiviswako<sup>®</sup> 105, 1.3 g of diisopropylamine, 15 2 g of glycerin, 5 g of 1,3-butyleneglycol, 30 g of ethanol, and 60.2 g of purified water.

20 After application of the test materials (A) and (B), the concentration of piroxicam in the serum was determined by the fluorometric method (measuring wavelength of 370 nm) according to a procedure proposed in a paper [Shichikawa et al., Rheumatism, No. 20, p.214 (1980), published by the Japan Society of Rheumatism].

Results

25 Results are shown in Table 3.

Table 3 Serum Concentration of Piroxicam ( $\mu\text{g}/\text{ml}$ )

Group	Time (hr)	1	3	6	AUC ( $\mu\text{g}\cdot\text{hr}\cdot\text{ml}^{-1}$ )
Soft patch according to Example 60	0.23	0.51	0.79	2.81	
Known preparation	0.02	0.29	0.18	1.03	

It thus disclosed that the preparation of this invention presents an AUC value about 2.7 times higher than a known preparation, and contributed to an increase of the percutaneous absorption of the drug.

- 42 -

CLAIMS

1. A soft pharmaceutical preparation for external application which contains the following components (a), (b), (c), (d) and (e) and has a stick-itself-to-the-skin property:
  - 5 (a) a drug;
  - (b) a water-soluble protein having an absorption promoting effect;
  - (c) a polyhydric alcohol;
  - (d) a tackifier; and
  - 10 (e) an oleaginous substance.
2. A pharmaceutical preparation according to claim 1, wherein an amount of the oleaginous substance is 0.5 to 20 weight percent, based on the weight of the whole composition.
3. A pharmaceutical preparation according to claim 1 or 2, 15 wherein an amount of the drug is 0.05 to 10 weight percent, based on the weight of the whole composition.
4. A pharmaceutical preparation according to claim 1, 2 or 3, wherein an amount of the water-soluble protein is 5 to 35 weight percent, based on the weight of the whole composition.
- 20 5. A pharmaceutical preparation according to any one of the preceding claims, wherein an amount of polyhydric alcohol is 5 to 35 weight percent, based on the weight of the whole composition.
6. A pharmaceutical preparation according to any one of the 25 preceding claims, wherein an amount of the tackifier is 0.3 to 10 weight percent, based on the weight of the whole composition.
7. A pharmaceutical preparation according to any one of the preceding claims, which also contains water.
- 30 8. A pharmaceutical preparation according to any one of the preceding claims, wherein the oleaginous substance is selected from esters of fatty acids, aliphatic higher alcohols, paraffin oils, lanolin oil, silicone oil and Plastibase.
- 35 9. A pharmaceutical preparation according to claim 8,

- 43 -

- wherein the oleaginous substance is one or more selected from esters of medium to higher fatty acids containing 6 to 20 carbon atoms and aliphatic monoools or triols containing 1 to 20 carbon atoms, or polyols containing 4 to 8 hydroxyl groups; aliphatic higher alcohols containing 14 to 20 carbon atoms; fluid paraffin; white petroleum; lanolin; and silicone.
10. A pharmaceutical preparation according to claim 9, wherein the oleaginous substance is a triglyceride of a medium to higher fatty acid containing 6 to 20 carbon atoms or an ester of said fatty acid and an aliphatic monoool containing 1 to 20 carbon atoms.
15. A pharmaceutical preparation according to any one of the preceding claims, wherein the drug is selected from drugs which exerts action on circulatory system, nervous system, endocrine system, respiratory system, metabolic system, urinary organ system or digestive organ system, antimicrobial agents, anti-tumor agents, vitamins, antidiabetics, enzymes, herb medicines and/or crude extracts.
20. 12. A pharmaceutical preparation according to any one of the preceding claims, wherein the water-soluble protein is selected from animal proteins, vegetable proteins or peptides, preferably from gelatin, solubilizable collagen, casein and soybean protein.
25. 13. A pharmaceutical preparation according to any one of the preceding claims, wherein the polyhydric alcohol has 2 to 6 of alcoholic hydroxyl groups.
30. 14. A pharmaceutical preparation according to any one of the preceding claims, wherein the tackifier is selected from cellulose derivatives, polysaccharides, carboxyvinyl polymers, polyvinyl alcohol and/or polyvinylpyrrolidone, preferably sodium alginate, sodium polyacrylate, alkyl cellulose, hydroxyalkyl cellulose, Karaya gum, carrageenan, polyvinyl alcohol, polyvinylpyrrolidone and Pluran.
35. 15. A pharmaceutical preparation according to any one of the

0159168

- 44 -

preceding claims, which also contains adsorption promoting auxiliaries, preservatives, emulsified-dispersants, pH-controlling agent and/or colors.